The interim protocol for the dispensing of adrenaline 150 microgram auto-injectors will cease to be in effect from 29 November 2018, the NHS has said.
Sufficient stock levels are now available of all three brands of junior and adult adrenaline auto-injectors, Jext, EpiPen and Emerade.
However, wholesaler prescription validation will remain in place for EpiPen only until further notice.
The shortage of EpiPens was first highlighted in May 2018 when the UK supplier Mylan identified shortcomings owing to manufacturing problems. Supplies of Jext and Emerade 0.15mg adrenaline auto-injectors were then rapidly depleted as a knock-on effect of the supply problems.